Aktuelle Aspekte und Strategien zum Einsatz oraler Antikoagulantien
                    und Plättchenfunktionshemmer in der Praxis

Christoph Sucker; Thomas Dörner

doi:10.1055/a-1857-5295

Aktuelle Rheumatologie, Inhaltsverzeichnis

Aktuelle Rheumatologie 2022; 47(06): 506-516
DOI: 10.1055/a-1857-5295

Übersichtsarbeit

Aktuelle Aspekte und Strategien zum Einsatz oraler Antikoagulantien und Plättchenfunktionshemmer in der Praxis

Current Aspects of Oral Anticoagulation and Platelet Inhibition in Clinical Practice

Christoph Sucker

¹Transfusion Medicine and Hemostasis, COAGUMED Gerinnungszentrum Berlin, Berlin, Germany

²Internal Medicine and Hemostasis, Medizinische Hochschule Brandenburg, Brandenburg an der Havel, Germany

,

Thomas Dörner

³Klinische Hämostaseologie, Med. Klinik mS Rheumatologie und Klinische Immunologie, Charité Universitätsmedizin Berlin, Germany

› Institutsangaben

Abstract

Zusammenfassung

Aufgrund erhöhter venöser und arterieller Risiken und Begleiterkrankungen bei entzündlich-rheumatischen Erkrankungen sind die Grundprinzipien der adäquaten medikamentösen Behandlung auch von Bedeutung in der rheumatologischen Praxis. Bei der oralen Antikoagulation haben die innovativen Nicht-Vitamin K-abhängigen oralen Antikoagulanzien (NOAK) die „klassischen“ Antikoagulanzien, die Vitamin K-Antagonisten (VKA), in vielen Indikationen weitgehend verdrängt; allerdings finden sich weiterhin Gründe, Patienten anstelle von NOAK mit VKA zu antikoagulieren. Bei der medikamentösen Hemmung der Plättchenfunktion werden neben ASS die Thienopyridine Clopidogrel und Prasugrel sowie Ticagrelor eingesetzt; von besonderer Bedeutung ist eine duale Plättchenfunktionshemmung (DAPT) mit Kombination verschiedener Plättchenhemmer. In dieser Übersichtsarbeit wird auf wichtige Aspekte der oralen Antikoagulation und der oralen Plättchenfunktionshemmung eingegangen.

Abstract

As patients with inflammatory rheumatic diseases have increased venous and arterial risks as well as concomitant diseases, the principles of antithrombotic treatment are of major relevance for rheumatologists. In many indications for oral anticoagulation, innovative non-vitamin K-dependent oral anticoagulants (NOAC) have widely replaced vitamin K antagonists (VKA), the traditional anticoagulants. However, there are still some clinical settings in which VKA should be used exclusively or preferentially for anticoagulation. Oral platelet inhibition may be achieved by ASS, thienopyridines (clopidogrel and prasugrel) and ticagrelor; dual antiplatelet treatment (DAPT) with a combination of ASS and other antiplatelet agents is of major importance. This review focuses on some important aspects of oral anticoagulation and oral inhibition of platelet function.

Schlüsselwörter

orale Antikoagulanzien - Vitamin K-Antagonisten (VKA) - Nicht-Vitamin Kabhängige orale Antikoagulanzien (NOAK) - Plättchenfunktionshemmer

Key words

oral anticoagulants - vitamin K antagonists (VKA) - antiplatelet agents - non-vitamin K-dependent oral anticoagulants (NOAC)online publiziert 2022

Volltext

Referenzen

Literatur
1 Roberti R, Iannone LF, Palleria C. et al. Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice. Front Pharmacol 2021; 26 (12) 684638 PMID: 34122113; PMCID: PMC8188985.
2 Sucker C, Litmathe J. Oral anticoagulation using coumarins – an update. Wien Med Wochenschr 2018; 168: 121-132
3 Chan N, Sobieraj-Teague M, Eikelboom JW. Direct oral anticoagulants: evidence and unresolved issues. Lancet 2020; 396: 1767-1776
4 Dunois C. Laboratory Monitoring of Direct Oral Anticoagulants (DOACs). Biomedicines 2021; 9
5 Sucker C, Litmathe J, Berthold K. MMW Fortschr Med 2019; 161 (Suppl 6) 15-23
6 Javed A, Ajmal M, Wolfson A. Dabigatran in cardiovascular disease management: A comprehensive review. World J Cardiol 2021; 13: 710-719
7 Voss F, Sucker C, Litmathe J. Anticoagulation after heart valve replacement. Wien Med Wochenschr 2021;
8 Ajmal M, Friedman J, Sipra QUAR. et al. Rivaroxaban: Expanded Role in Cardiovascular Disease Management-A Literature Review. Cardiovasc Ther 2021; (08) 2021: 8886210 PMID: 33505518; PMCID: PMC7810545.
9 Koehl JL, Hayes BD, Al-Samkari H. et al. A comprehensive evaluation of apixaban in the treatment of venous thromboembolism. Expert Rev Hematol 2020; 13: 155-173
10 Seeger J, Wöhrle J. Apixaban: An Update of the Evidence for Its Place in the Prevention of Stroke in Patients with Atrial Fibrillation. Core Evid 2020; 15: 1-6
11 Srinivasan S, Ajmal M, Pecci C. et al. Edoxaban in cardiovascular disease management: Review. Br J Clin Pharmacol 2022; 88: 535-540
12 AWMF-Leitlinie. Rückenmarksnahe Regionalanästhesien und Thromboembolieprophylaxe/ antithrombotische Medikation. S1-Leitlinie. Stand 20.05.2021. AWMF-Registernummer: 001-005
13 Beyer-Westendorf J, Gelbricht V, Förster K. et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J 2014; 35: 1888-1896
14 Koscielny J, Rutkauskaite E, Sucker C. et al. How do I reverse oral and parenteral anticoagulants?. Hämostaseologie 2020; 40: 201-213
15 Witt DM. Approaches to optimal dosing of vitamin K antagonists. Semin Thromb Hemost 2012; 3: 667-672
16 Brouwer JL, Stoevelaar H, Sucker C. The clinical impact of different coagulometers on patient outcomes. Adv Ther 2014; 31: 639-656
17 Sucker C, Hager A, Koscielny J. et al. Orale Antikoagulation: Aktuelle Übersicht und perioperatives Management in der Ophthalmochirurgie [Oral anticoagulation: Current overview and perioperative management in ophthalmic surgery]. Ophthalmologe 2019; 116: 144-151
18 Watzka M, Geisen C, Scheer M. et al. Bleeding and non-bleeding phenotypes in patients with GGCX gene mutations. Thromb Res 2014; 134: 856-865
19 Ballal P, Peloquin C, Boer CG. et al. Warfarin use and risk of knee and hip replacements. Ann Rheum Dis 2021; 80: 605-609
20 Boer CG, Szilagyi I, Nguyen NL. et al. Vitamin K antagonist anticoagulant usage is associated with increased incidence and progression of osteoarthritis. Ann Rheum Dis 2021; 80: 598-604
21 Eun MY, Kim JY, Hwang YH. et al. Initiation of Guideline-Matched Oral Anticoagulant in Atrial Fibrillation-Related Stroke. J Stroke 2021; 23: 113-123
22 AWMF Leitlinie. Venenthrombose und Lungenembolie: Diagnostik und Therapie. S2k Leitlinie. Stand: 10.10.2015. AWMF-Leitlinien-Registernummer: 065-002
23 Tektonidou MG, Andreoli L, Limper M. et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019; 78: 1296-1304
24 Bauersachs R, Langer F, Kalka C. et al. Treatment of the antiphospholipid syndrome with direct oral anticoagulants. Position statement of German societies. Vasa 2019; 48: 483-486
25 Sucker C, Dafotakis M, Litmathe J. Focus on direct oral anticoagulants (DOAC) for prophylaxis of venous thrombosis and pulmonary embolism in medically ill patients. Int J Cardiol 2016; 203: 454-456
26 Pollack CV, Wang TY. Evolution of Clinical Thinking and Practice Regarding Aspirin: What Has Changed and Why?. Am J Cardiol 2021; 144 (Suppl 1) 10-14
27 Weber AA, Adamzik M, Bachmann HS. et al. Interdisciplinary Study Group - Clinical Pharmacology of Haemostasis. Methods to evaluate the pharmacology of oral antiplatelet drugs. Herz 2008; 33: 287-296
28 Zimmermann N, Weber AA, Hohlfeld T. Aspirin “resistance”. Herz 2008; 33: 270-278
29 Darius H. Duale Thrombozytenhemmung nach akutem Koronarsyndrom oder perkutaner Koronarintervention – womit und wie lange?. Internist 2021; 62: 1243-1252
30 Karunawan NH, Pinzon RT. Prevalence of Aspirin and Clopidogrel Resistance in Patients with Recurrent Ischaemic Cerebrovascular Disease. Eur Cardiol 2021; 16: e72 PMID: 35106088; PMCID: PMC8785077
31 Fachinformation Brilique^® 90 mg Filmtabletten. Astra Zeneca. Stand der Information: März 2021
32 Korte W, Cattaneo M, Chasson PG. et al. Peri-operative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the working group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the working group on Perioperative Coagulation of the Austrian Society for Anesthesiology, Resuscitation and Intensive Care (ÖGARI) and the Working Group Thrombosis of the European Society for Cardiology (ESC). Thromb Haemost 2011; 105: 743-749
33 Schlitt A, Jámbor C, Spannagl M. et al. The perioperative management of treatment with anticoagulants and platelet aggregation inhibitors. Dtsch Arztebl Int 2013; 110: 525-532
34 Creager MA. Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events. Vasc Med 1998; 3: 257-260
35 Gent M, Beaumont D, Blanchard M. CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339
36 Steffel J, Eikelboom JW, Anand SS. et al. The COMPASS Trial: Net clinical benefit of low-dose rivaroxaban plus aspirin as compared with aspirin in patients with chronic vascular disease. Circulation 2020; 142: 40-48
37 Birocchi S, Scanella E, Ferrari L. et al. Gruppo di Autoformazione Metodologica (GrAM). Aspirin in the secondary prevention of unprovoked thromboembolism: the WARFASA and ASPIRE studies. Intern Emerg Med 2013; 8: 757-760
38 Fachinformation Clopidogrel ratiopharm GmbH 75 mg Filmtabletten. Ratiopharm. Stand der Information: August 2019
39 Jakubowski JA, Erlinge D, Alexopoulos D. et al. The Rationale for and Clinical Pharmacology of Prasugrel 5 mg. Am J Cardiovasc Drugs 2017; 17: 109-121
40 Wiviott SD, Braunwald E, McCabe CH. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015
41 Gebrauchsinformation: Informationen für Anwender. Efient 10 mg/ 5 mg Filmtabletten. Daiichi-Sankyo. Stand: Oktober 2020
42 Wallentin K, Becker RC, Budaj A. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057
43 Lüscher TF. Dual antiplatelet therapy: how, how long, and in which patients. Eur Heart J 2018; 39: 181-183